| IgA Nephropathy | Name or Title of Research Study
A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN)
| Enrollment Criteria
Male or female who is 18+ years of age, diagnosed with IgAN with biopsy verification within 10 years prior to study, on a stable dose of RAS inhibitor therapy, and has an eGFR of at least 30 mL/min/1.73 m2 | | Treatment: Atacicept v. Placebo | | Sponsor: Vera Therapeutics | Institution: University of Florida Nephrology
PI: Dr. Wai Lang Lau
Contact for Enrollment
Karine Charles, BS, Coordinator II
Karine.charles@medicine.ufl.edu | 352-294-5068
|
| IgA Nephropathy |
|
Name or Title of Research Study
Povetacicept in autoimmune kidney disease
|
|
Link to Trial Information
https://clinicaltrials.gov/study/NCT05732402?cond=Povetacicept&rank=2
|
Institution
CFLKS and NCCF.r
Contact for Enrollment
Arvind Madan, MD
amadan@cflks.com
(407) 230-5269
Cflks.com |
| IgA Nephropathy |
|
Title of Research Study
PROTECT: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL-GROUP, ACTIVE-CONTROL STUDY OF THE EFFICACY AND SAFETY OF SPARSENTAN FOR THE TREATMENT OF IMMUNOGLOBULIN A NEPHROPATHY
|
| PI: Dr. Contreras, Dr. Drexler, Dr. Fornoni |
| Sponsor: Retrophin Inc. |
| Drug: Sparsentan |
|
Institution: UM Nephrology
Contact for Enrollment:
Jacqueline Vassallo, CCRP.
jvassall@med.miami.edu
Tel: 305-243-4691
|
| IgA Nephropathy |
|
Title of Research Study
OMEROS OMS721-IGA-001: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF THE SAFETY AND EFFICACY OF OMS721 IN PATIENTS WITH IMMUNOGLOBULIN A (IGA) NEPHROPATHY (ARTEMIS - IGAN)
|
| PI: Dr. Contreras, Dr. Sosa |
| Sponsor: Omeros Corporation |
| Drug: OMS721 |
|
Institution: UM Nephrology
Contact for Enrollment:
Jacqueline Vassallo, CCRP.
jvassall@med.miami.edu
Tel: 305-243-4691
|
IgA, FSGS, MN, MCD
|
|
Title of Research Study: NEPTUNE: The Nephrotic Syndrome Study Network
|
| PI: Dr. Fornoni, Dr.Contreras, Dr. Lenz |
| Sponsor: NIH-Office of Rare Kidney Disease-NIDDK, DHHS-NephCure Kidney International, The University of Michigan |
| Active/Enrolled/InScreening: 4/51/1 |
|
Institution: UM Nephrology
Contact for Enrollment:
Jacqueline Vassallo, CCRP.
jvassall@med.miami.edu
Tel: 305-243-4691
|
IgA, FSGS, MN, MCD
|
|
Title of Research Study: CureGN: Cure Glomerulonephropathy Network
|
| PI: Dr. Fornoni, Dr.Contreras, Dr. Lenz
|
| Sponsor: NIH-NIDDK-NephCure Kidney International |
| Active/Enrolled/InScreening: 7/10/0 |
|
Institution: UM Nephrology
Contact for Enrollment:
Jacqueline Vassallo, CCRP.
jvassall@med.miami.edu
Tel: 305-243-4691
|
|
Florida Women in Nephrology Chair
FSN President
Print Page